To determine the frequency of TERE1 alteration in human prostate cancers we conducted an immuno-histochemical analysis using a custom human prostate tumor microarray (TMA) to examine TERE1 expression in primary carcinoma compared to metastatic specimens. This evidence concerns the gene UBIAD1 and prostate cancer.